Abstract
The majority of lower-risk myelodysplastic syndromes/neoplasms patients present with anemia. Historically, these patients were treated with erythropoiesis-stimulating agents (ESA), with modest responses. A subset of these patients with del(5q) may do better with lenalidomide. Recently, in randomized trials, luspatercept has shown better responses compared with ESAs in treatment-naive patients and imetelstat in patients refractory to ESAs. Other evaluated novel compounds (fostamatinib, H3B-880, roxadustat, pyruvate kinase receptor activator) have not yet shown meaningful efficacy. More needs to be done to improve outcomes; in pursuance of this, participation in clinical trials evaluating novel therapies should be encouraged. While lower-risk myelodysplastic syndromes/neoplasms tend to have an indolent course, a subset of them has a dismal prognosis. Improving prognostication and serial monitoring will help in identifying high-risk patients for appropriate management.
Original language | English (US) |
---|---|
Pages (from-to) | 1877-1889 |
Number of pages | 13 |
Journal | Future Oncology |
Volume | 19 |
Issue number | 27 |
DOIs | |
State | Published - Sep 1 2023 |
Externally published | Yes |
Keywords
- AML
- MDS
- prognosis
- risk stratification
- somatic mutations
- targeted drugs
ASJC Scopus subject areas
- Oncology
- Cancer Research